Is Johnson & Johnson (JNJ) Halal?
Screener: Yes — Johnson & Johnson passes Shariah screening as of October 2026. Its business is halal, its debt is 7.69% of market cap, and its interest income is 0.91% of revenue. Below: the full screening math, the question every investor asks, and the caveats that could change the answer.
Screen 1: Business activity
Johnson & Johnson is a healthcare company operating in two segments: Innovative Medicine (pharmaceuticals — immunology, oncology, neuroscience, and more) and MedTech (medical devices and surgical technology, including the Ottava robotic surgery platform cleared by the FDA). None of its core businesses are in prohibited industries (alcohol, gambling, conventional finance, weapons, adult entertainment, non-halal food).
The ongoing talc litigation (with a proposed settlement framework announced in 2026) is a legal and contingent-liability matter — it does not change the business-activity screen, which looks at what the company does, not the lawsuits it faces.
Screen 2: Financial ratios
AAOIFI-style screening applies three ratio tests:
| Ratio | Johnson & Johnson (Oct 2026) | Ceiling | Result |
|---|---|---|---|
| Total debt ÷ market cap | 7.69% ($49.0B (loans and notes payable $11,692M + long-term debt $37,344M) on $638.0B market cap) | < 33% | PASS |
| Cash + short-term investments ÷ market cap | 3.25% ($20.8B (cash $20,422M + marketable securities $336M) on $638.0B market cap) | < 33% | PASS |
| Non-compliant income ÷ total revenue | 0.91% ($448M interest income on $49,372M sales to customers (H1 2026)) | < 5% | PASS |
Figures: Q2 2026 10-Q (filed July 23, 2026) for revenue, debt, and cash (six months ended June 28, 2026); market data September 30, 2026 close ($638.0B market cap at $264.74/share on 2,409.9M outstanding as of July 17, 2026).
Screen 3: Purification
Johnson & Johnson pays a quarterly dividend. With non-compliant income at 0.91% of revenue, the purification amount on that dividend is small — but if you follow a strict methodology, run any dividends through our purification calculator.
What could change the screener
- A debt-funded mega-acquisition. At 7.69%, J&J has solid headroom — but the company does use debt for acquisitions, so a very large debt raise would be worth re-checking.
- A business-mix shift. A move into a prohibited industry at meaningful scale would require re-examination of the business-activity screen.
- Rising interest income. Currently 0.91%; a large and growing cash pile earning interest would show up in the 5% income screen first.
We re-screen on a quarterly cadence — the screener above reflects the latest SEC filing and September 30, 2026 market data.
How Canadians buy it
Johnson & Johnson trades only on the NYSE as JNJ — there is no TSX listing, so you buy in USD. To convert cheaply, use Norbert's gambit on Questrade rather than paying a broker's conversion spread. JNJ is available through Questrade and Wealthsimple's self-directed accounts, and it can be held in a TFSA, RRSP, or FHSA — all wrappers are neutral to Shariah compliance. See our Questrade vs Wealthsimple comparison for the practical differences.
Screened with our two-gate Shariah screening methodology (business-activity gate, then AAOIFI-style financial ratios).
FAQ
Is Johnson & Johnson halal to invest in?
As of October 2026: yes, it passes Shariah screening — a halal pharmaceuticals and MedTech business, 7.69% debt ratio, 0.91% interest income. This is a screening result, not a religious ruling.
Do I need to purify J&J's dividend?
Johnson & Johnson pays a quarterly dividend. With non-compliant income at 0.91% of revenue, the purification amount on it is small — but if you follow a strict methodology, you can run any dividends through a purification calculator.
J&J carries about $49 billion in debt — doesn't that fail the debt screen?
The screen compares debt to market value, not to zero. J&J's ~$49.0B in total debt is about 7.69% of its ~$638.0B market cap — far under the 33% ceiling. The absolute number sounds large; the ratio is what the methodology measures.
What if J&J becomes non-compliant after I buy?
The common guidance: sell the holding (scholars differ on timing when it's at a loss — ask a qualified scholar), purify the non-compliant share of any dividends received, and don't offset other gains against it. Re-screen quarterly; we'll update this page when the numbers move.